Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
June 7, 2026Diabetes

1764-P: Inflammation, Body Mass Index, and Cardiovascular Outcomes in Chronic Kidney Disease and Type 2 Diabetes

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Does finerenone reduce composite CV events irrespective of baseline hsCRP and BMI in adults with CKD and T2D?

Population

12,864 adults with chronic kidney disease (CKD) and type 2 diabetes (T2D)

Design

Meta-analysis

Authors

JOJohn OstrominskiGFGERASIMOS FILIPPATOSPRPETER ROSSING

Discussion

Loading...

Member takes

Overview

In patients with CKD and T2D, low-grade inflammation is associated with increased CV risk, particularly in those with overweight/obesity, but the CV benefits of finerenone remain consistent regardless of baseline hsCRP or BMI.

Key Points

  • This research aims to explore the connection between inflammation and obesity, particularly regarding cardiovascular risks in individuals with chronic kidney disease and type 2 diabetes.
  • Participant-level pooled analysis from the FIDELITY program
  • Assessed hsCRP and BMI association among 12,864 adults with CKD and type 2 diabetes
  • Evaluated cardiovascular outcomes based on hsCRP levels and BMI categories.
  • 53% of participants had elevated hsCRP (≥2 mg/L) at baseline.
  • Elevated hsCRP levels correlated with a higher rate of composite cardiovascular events (aHR 1.11; 95% CI, 1.07-1.14).
  • Risk associations were significant particularly in those with elevated BMI (Pinteraction=0.002).

Structured PICO

Does finerenone reduce composite CV events irrespective of baseline hsCRP and BMI in adults with CKD and T2D?

P
Population
12,864 adults with chronic kidney disease (CKD) and type 2 diabetes (T2D)
I
Intervention
Finerenone
O
Outcome
Composite CV eventscomposite

In patients with CKD and T2D, low-grade inflammation is associated with increased CV risk, particularly in those with overweight/obesity, but the CV benefits of finerenone remain consistent regardless of baseline hsCRP or BMI.

Cite This Study

Ostrominski et al. (2026) studied this question.

synapsesocial.com/papers/6a250c1c7def13d035e1c19dhttps://doi.org/10.2337/db26-1764-p
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 11404-P: Obesity Drives Cardiac Hypertrophy while Diabetic Kidney Disease Links to Myocardial Edema and Vascular Stiffness in Young Adults with Type 2 Diabetes2026
  2. 21427-P: Fibrosis-4 Index Is Associated with ASCVD Burden, MACE, and Mortality in Real-World Type 2 Diabetes Cohort2026
  3. 3Incretin-based therapy for heart failure with reduced ejection fraction: why we need a trial2025 · 1 citations
  4. 41824-P: The Association of Dipeptidyl Peptidase-4 Inhibitors (DPP-4i) with Cardiovascular Outcomes in People with Type 2 Diabetes from the UK Clinical Practice Research Datalink (CPRD)2026
  5. 5Biomarkers for cardiovascular–kidney metabolic syndrome: Clinical utility in diagnosis, screening, and treatment2025 · 6 citations